In a nutshell This trial is examining the effectiveness and safety of single-hormone closed-loop (SHCL) compared with sensor-augmented pump therapy (SAPT) in controlling glucose levels in patients with type 1 diabetes (T1D). The main outcome to be measured will be the percentage of time that glucose levels are between 3.9 and 10...
Read MoreClinical Trial Posts on Medivizor
Searching for patients with metastatic castration resistant prostate cancer to test a targeted therapy option
In a nutshell This phase 2 trial is examining the effectiveness and safety of trametinib (Mekinist) in patients with metastatic castration-resistant prostate cancer (mCRPC; prostate cancer which has spread from its original place to another area in the body and keeps growing even when the amount of testosterone in the body...
Read MoreSearching for patients with non-small cell lung cancer to test this new treatment combination
In a nutshell This phase 2 trial is examining the effectiveness and safety of navarixin (MK-7123) in combination with pembrolizumab (Keytruda) in patients with non-small cell lung cancer (NSCLC). The main outcome to be measured will be the objective response rate (ORR; tumor shrinkage or disappearance). The details A treatment option for...
Read MoreSearching for patients with colorectal cancer to test this new treatment combination
In a nutshell This phase 2 trial is examining the effectiveness and safety of navarixin (MK-7123) in combination with pembrolizumab (Keytruda) in patients with colorectal cancer (CRC). The main outcome to be measured will be the objective response rate (ORR; tumor shrinkage or disappearance). The details A treatment option for patients with...
Read MoreSearching for patients with prostate cancer to test this new treatment combination
In a nutshell This phase 2 trial is examining the effectiveness and safety of navarixin (MK-7123) in combination with pembrolizumab (Keytruda) in patients with castration-resistant prostate cancer (CRPC; cancer that progresses after hormonal therapy). The main outcome to be measured will be the objective response rate (ORR; tumor shrinkage or...
Read MoreSearching for patients with lung cancer that cannot be operated on to test durvalumab after chemotherapy and radiation
In a nutshell This phase 2 trial will investigate the safety and effectiveness of durvalumab (Imfinzi) in patients with stage III non-small cell lung cancer (NSCLC). The main outcomes will be the number of treatment-related adverse events (TRAEs) and progression-free survival (PFS). The details Non-small cell lung cancer (NSCLC)...
Read MoreSearching for patients with relapsed or unresponsive non-Hodgkin lymphoma to try a new cell therapy
In a nutshell This Phase 2 study is evaluating the safety and effectiveness of a new T-cell therapy for B-cell non-Hodgkin’s lymphoma (NHL) that has come back or stopped responding to treatment. The main outcomes to be measured will be the number of patients who experience side effects and overall response after treatment. This trial is recruiting...
Read MoreSearching for patients to try a new treatment combination for untreated acute myeloid leukemia.
In a nutshell This trial is searching for patients to try a combination of glasdegib (Daurismo) with azacitidine (Vidaza) for acute myeloid leukemia (AML) that has not been treated. The main outcome that will be measured is overall survival. The details Different anti-cancer drugs can be used in different combinations and may have different effects....
Read MoreLooking for patients who have had a stroke to investigate factors to predict recovery
In a nutshell This trial is examining the predictive factors for stroke recovery. The main outcomes to be measured will be the change in hand movements after the stroke. This study is being conducted in Baltimore, Maryland, US. The details During a stroke, brain cells die due to the limited blood flow to the brain. When this happens, the abilities...
Read MoreLooking for patients with Ph+ or BCR-ABL+ acute lymphoblastic leukemia to test a treatment combination
In a nutshell This phase 2 trial is evaluating the effectiveness of ponatinib (Iclusig) plus chemotherapy for patients with acute lymphoblastic leukemia (ALL) that is positive for the Philadelphia chromosome (Ph+) or the BCR-ABL gene (BCR-ABL+). The main outcome to be measured will be the number of patients who respond to treatment. This study is...
Read MoreLooking for older patients with acute myeloid leukemia to test a new treatment combination
In a nutshell This study is evaluating how well CPI-613 plus chemotherapy works in older patients with acute myeloid leukemia (AML) that has come back or stopped responding to treatment. The main outcome to be measured will be the number of patients who have a complete disappearance of all signs of cancer. This trial is taking place across the United...
Read MoreLooking for young patients with non-Hodgkin’s lymphoma to test a treatment combination
In a nutshell This phase 3 trial is comparing the effectiveness of ibrutinib (Imbruvica) plus chemotherapy versus chemotherapy alone in children and young adults with B-cell non-Hodgkin’s lymphoma (NHL). The main outcome to be measured will be survival without cancer returning, growing or spreading. The details Ibrutinib is a targeted therapy...
Read More
